Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Desperate for relief: one patient gets experimental stem cell infusions for chronic pain

NCT ID NCT04711811

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended) This study
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial gave multiple infusions of a patient's own stem cells to treat chronic muscle and joint pain that had lasted at least a year. The patient received six infusions over about 32 weeks, with safety checks and pain scores tracked throughout. The goal was to see if this approach could safely ease pain and improve daily life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
patient's own stem cells (Hope Biosciences adipose derived autologous mesenchymal stem cells)
What this could lead to
If it works, this could point toward a way to reduce chronic pain without long-term medication.
What could go wrong
This was a very small, early access program for just one patient, so results may not apply to others. The treatment is still experimental and unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

IND # 27057 Inclusion Criteria: 1. Subject is \> 18 years of age at the time of signing the informed consent form. 2. Subject has the diagnosis of chronic musculoskeletal pain for a least 1 year or VAS score \> 7 a screening visit. 3. Subject has provided informed consent before initiation of any study procedure. 4. Subject and sexual partner if woman of childbearing potential must use a least 1 highly effective form of birth control\* throughout the study and for 6 months after the last dose of the investigational product. Exclusion Criteria: 1. Subject has any active infection for which antibiotics were indicated within 4 weeks before screening. 2. Subject has known alcoholic addiction or dependency, uses alcohol daily, or has current substance use or abuse. 3. Subject has any active malignancy, including evidence of cutaneous basal, squamous cell carcinoma, or melanoma. 4. Subject has 1 or more significant concurrent medical conditions per investigator judgment, including the following: * poorly controlled diabetes. * chronic kidney disease * heart failure * myocardial infarction or unstable angina within 6 months prior to screening. * uncontrolled hypertension 5. Subject has received any stem cell treatment within 12 months before first dose of investigational product. 6. Subject has laboratory abnormalities during screening, including the following: * White blood cell count \< 3000/mm3 * Platelet count \< 125,000mm3 * Absolute neutrophil count \< 1500/mm3 * Subject has any other laboratory abnormality, which, in the opinion of the investigator poses a safety risk or will prevent the subject for completing the study. 7. Subject is currently receiving treatment in another investigational drug study. 8. Subject is unlikely to complete the study or adhere to the study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hope Biosciences Stem Cell Research Foundation

    Sugar Land, Texas, 77478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.